Driving the future of CAR-T cell therapies

Using a multipronged strategy, Celyad is driving the development of next-generation chimeric antigen receptor-T cell-based therapies to treat cancer. Lead programs include both autologous and allogeneic clinical candidates, and the company is also expanding its pipeline through internal development and external partnerships

Jun 10, 2019
0
0
Page of

Celyad

Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based product candidates and utilizes its expertise in cell engineering to target cancer. Celyad’s CAR-T cell platform has the potential to treat a broad range of solid and hematologic tumors. The company’s lead clinical candidate, CYAD-01, an autologous NKG2D-based CAR-T therapy, is currently being evalu-ated in several Phase 1 clinical trials to assess safety and clinical activity for the treatment of hematological malignancies, such as acute myeloid leukemia, and solid cancers, such as metastatic colorectal cancer. Celyad is also developing CYAD-101, an investigational, non-gene edited, allogeneic (donor derived) NKG2D-based CAR-T therapy, which is currently being evaluated in a Phase 1 trial for the treatment of patients with metastatic colorectal cancer. Celyad was founded in 2007 and is based in Mont-Saint-Gui-bert, Belgium, and New York, NY. Celyad’s ordinary shares are listed on the Euronext Brussels and Euron-ext Paris exchanges, and its American Depository Shares are listed on the Nasdaq Global Market, all under the ticker symbol CYAD.

No comments yet.